Atossa Therapeutics, Inc. (ATOS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Atossa Therapeutics, Inc. (ATOS) closed at USD 2.78 on 2026-10-14, a change of -80.3 % over the past year, with a market capitalization of USD 26.45M.

Atossa Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Atossa Therapeutics, Inc. key figures

Previous close

USD 2.78 (2026-10-14)

1-year change

-80.3 %

Market cap

USD 26.45M

Enterprise value

USD 351,139

P/E ratio (trailing)

-0.60

P/E ratio (forward)

-0.80

EPS (trailing)

-4.45

EPS (forward)

-3.30

PEG ratio

n/a

Price to book

0.99

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.35

Employees

16

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Atossa Therapeutics, Inc. and compare it with other stocks.